Beyond safety: suicide systems in cell-based cancer therapies

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Solid tumors present challenges for cell-based therapies including heterogeneity, antigen escape, and immunosuppressive microenvironments.
• Inducible suicide gene systems are primarily safety features for therapeutic cells.
• Controlled elimination of therapeutic cells can be achieved via these systems.

Purpose of the Study:

• To explore the underappreciated potential of inducible suicide gene systems in enhancing cell-based cancer therapies.
• To highlight how controlled cell death can overcome limitations in treating solid tumors.
• To emphasize the dual role of these systems in improving efficacy and ensuring safety.

Main Methods:

• Review of recent developments in inducible suicide gene systems for cell therapy.
• Analysis of mechanisms triggering controlled cell death (prodrugs, ligands, antibodies, small molecules).
• Investigation of immunogenic cell death (ICD) induction and its impact on tumor microenvironment (TME).

Main Results:

• Controlled cell death, particularly via ICD, can eliminate resistant tumor cells.
• Inducible suicide systems can reprogram the immunosuppressive TME into a stimulatory one.
• These systems offer a method to amplify antitumor responses.

Conclusions:

• Integrating inducible suicide gene systems into cell therapies holds transformative potential.
• These systems can overcome critical efficacy barriers in solid tumor treatment.
• The controlled elimination of cells enhances safety while amplifying therapeutic outcomes.